Interim data from phase III HELP OLE study of Takhzyro shows efficacy in hereditary angioedema.- Takeda
Takeda Pharmaceutical announced findings from two new interim analyses of data from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), suggesting Takhzyro (lanadelumab) is… read more.